Oppenheimer & Co’s Emergent Biosolutions EBS Stock Holding History

Oppenheimer & Co’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4,240	Closed	-$438K	–	1362
2020 Q3	$438K	Buy	4,240 +78	+2%	+$8.41K	0.01%	858
2020 Q2	$329K	Buy	+4,162	New	+$310K	0.01%	934
2014 Q2	–	Sell	-15,500	Closed	-$392K	–	1427
2014 Q1	$392K	Buy	+15,500	New	+$391K	0.01%	924

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Oppenheimer & Co's EBS Position: Q4 2020 in Review

Oppenheimer & Co sold out of Emergent Biosolutions (EBS) in Q4 2020, closing a stake of 4,240 shares — an estimated $438K sold.

Oppenheimer & Co first reported a position in EBS in Q1 2014 and held it in 3 quarters. The position peaked at $438K in Q3 2020. 353 funds tracked by Wall St. Rank hold EBS as of Q4 2020.

Oppenheimer & Co reported no remaining Emergent Biosolutions position as of Q4 2020 after selling out during the quarter.
Oppenheimer & Co sold 4,240 Emergent Biosolutions shares in Q4 2020, an estimated $438K.
Oppenheimer & Co first reported a position in Emergent Biosolutions in Q1 2014 and held it in 3 quarters.
Oppenheimer & Co's Emergent Biosolutions position peaked at $438K in Q3 2020.
353 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2020.

Based on Oppenheimer & Co's 13F filing for Q4 2020, filed 11 Feb 2021.